BYSL

Across TCGA pan-cancer cohorts, BYSL mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated BYSL data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BYSL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BYSL expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

HNSC, LSCC, and LUAD are the cancer types where BYSL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.647	0.894	.003	29	view →
LSCC	DFS	Quartile	II,III,IV	0.945	0.455	.001	24	view →
LUAD	DFS	Tertile	All	0.508	1.000	.014	11	view →
PDAC	DFS	Median	III,IV	0.485	0.238	.016	10	view →
GBM	OS	Tertile	All	0.657	0.253	.008	7	view →
CCRCC	OS	Quartile	III,IV	0.135	0.985	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

BYSL–HNSC (DFS)

Open the HNSC breakdown →